Ulf Jonsson Appointed CEO of Cellectricon
Gothenburg, Sweden. Cellectricon is pleased to announce that Ulf Jonsson has accepted the position as Chief Executive Officer of the Company effective January 1, 2005. The appointment is a result of an extensive international search in conjunction with the planned resignation of Jakob Lindberg (co-founder).
Ulf Jonsson, Ph. D in Applied Physics, has previously served as CEO at Biacore. He has also worked for Pharmacia Biotechnology/ Amersham Bioscience where he served as Marketing Manager for Molecular Biological Systems. Ulf Jonsson has an impressive track record spanning more than 20 years in the biotechnology industry, with deep research experience as well as sucessfully developing a company from start to listing.
Ulf Jonsson said: "I've followed Cellectricon's development with great interest and I am privileged to become the new Chief Executive Officer. I'm especially impressed by the DynaflowTM technology that offers proven productivity increase together with enhanced data quality and information content vis-a-vis all other ion-channel assays (including patch-clamp). I'm looking forward to expanding the DynaflowTM product range and develop the remarkable potential of Cellectricon's extensive IP portfolio with novel cell-based technologies".
Cellectricon's Chairman Axel Broms added: "Cellectricon has in the last year successfully introduced Dynaflow(TM) in the life-science market. Cellectricon has testimonials from top reference customers that validate the commercial value of Dynaflow(TM) for its targeted application - ion channel drug discovery. I am very excited that Ulf Jonsson has agreed to join Cellectricon when we are rolling out Dynaflow(TM) on a global basis at the same time as expanding the Dynaflow(TM) product range. Ulf has the skill and track record to take Cellectricon to its next phase - from successfull start-up Company to key life-science industry player".
About Cellectricon
Cellectricon AB (Gothenburg, Sweden) develops life science tools based on world leading science competences. The products target bottlenecks in the drug discovery process. The first generation of products, DynaflowTM, is a groundbreaking tool for ion channel drug discovery and offers dramatic productivity increase with major savings in both time and cost. DynaflowTM has been well received and has already been adopted by more than eight of the world's leading pharmaceutical companies. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation. Cellectricon is a privately held company and the main shareholders are InnovationsKapital, Investor Growth Capital and Karolinska Investment Fund.
Other news from the department people
